Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
9 Meters Biopharma
AddedFeb 19, 2024
UpdatedJun 18, 2026
9 Meters Biopharma

9 Meters Biopharma

Closed

9 Meters Biopharma: A gastrointestinal platform dedicated to addressing rare disorders and unmet needs.

HQ
Raleigh, NC, US
Founded
2010
Overview
Compare
Fundraising
Employees
Website

9 Meters Biopharma, founded with a mission to address rare gastrointestinal disorders and unmet medical needs, is a specialized biopharmaceutical company. The company focuses on developing innovative treatments for patients suffering from conditions that lack effective therapeutic options. Their product pipeline includes novel therapies targeting specific gastrointestinal diseases, aiming to improve the quality of life for patients with these challenging conditions.

Notable figures affiliated with 9 Meters Biopharma include experienced professionals in the biopharmaceutical industry, although specific names are not provided. The company has attracted significant investment to support its research and development efforts. Key achievements include advancing multiple drug candidates through various stages of clinical trials, demonstrating their commitment to bringing new treatments to market. Overall, 9 Meters Biopharma has made a substantial impact in the field of gastrointestinal health by focusing on rare and underserved patient populations.

9 Meters Biopharma - Quick Facts

When was 9 Meters Biopharma founded?

9 Meters Biopharma was founded in 2010.

Where is 9 Meters Biopharma's headquarters located?

9 Meters Biopharma's headquarters is located in Raleigh, NC, US.

When was 9 Meters Biopharma's last funding round?

9 Meters Biopharma's most recent funding round was for $5M (USD) in March 2023.

How much has 9 Meters Biopharma raised to-date?

As of Mar 14, 2023, 9 Meters Biopharma has raised a total of $129.5M (USD).

9 Meters Biopharma - Classification

Ownership
  • Public
Technology
  • HealthTech
  • SaaS
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Biotech
Tags
  • Software
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations
ISIC
  • 2100Manufacture of pharmaceuticals, medicinal chemical and botanical products
Show 23 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 334100Computer and Peripheral Equipment Manufacturing
  • 334112Computer Storage Device Manufacturing
  • 330000Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 334000Computer and Electronic Product Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 334110Computer and Peripheral Equipment Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 3572Computer Storage Devices
  • 3500Industrial And Commercial Machinery And Computer Equipment
  • 4000Railroad Transportation
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 3570Computer And Office Equipment
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research
ISIC
  • 2620Manufacture of computers and peripheral equipment